Blood Disorders Market Analysis and Forecasts Report to 2013

Blood Disorders Market Analysis and Forecasts Report to 2013

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:

Antithrombotics


• Anti-anaemics
  
  
• Clotting Factors
  
  
• Others

In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales and bring in significant profits or will it be rocked by widespread patent expiration and ensuing generic competition? This report provides these answers, with detailed quantitative and qualitative analysis. This is information every player in the blood diseases treatments market should not be without.

Visiongain’s new Blood Disorders 2008 report covers:

• An in-depth analysis of the major blood diseases and treatments
  
  
• Discussion of most effective innovative treatments for blood diseases
  
  
• Trends in the overall world blood diseases treatments market, with detailed market forecasts from 2008 to 2023
  
  
• Reasons behind the trends
  
  
• A breakdown of the world market into the principal market segments, with forecasts and predictions of future market share values
  
  
• Sales forecasts of the leading drugs in each sub-market
  
  
• A SWOT analysis of the blood disorders market
  
  
• Discussion of relevant market drivers and restraints
  
  
• A geographical breakdown of relevant global sales trends into the leading national markets
  
  
• Pipeline developments in blood disorders

This study was achieved through research of relevant news, company reports, expert opinion, academic literature and gold-standard IMS databases. Financial forecasting based upon in-depth research was performed, with accompanying SWOT analyses. The result is a comprehensive market-based study with extensive analysis and informed opinion.

Why You Should Buy This Report

This 115+ page report features over 25 tables, 50 graphs, market forecasts, current news, detailed insight, the latest developments, all with up-to-date analysis and informed opinion. This visiongain report is a vital aid to your gaining an understanding of this important market sector, giving your company 'the edge' on its competitors.

Importantly report gives answers to relevant questions such as:

• How will sales for blood disorder treatments change from 2006-2013 and beyond?
  
  
• What is the market share of the four classes of treatments and how will they change in the years ahead?
  
  
• What are the top ten drugs in the blood diseases treatments market currently - how will they fare from now until 2013?
  
  
• Which group of treatments will contract the most over the next five years?
  
  
• Which drugs dominate each treatment group, present and future?
  
  
• What are the main issues facing the market worldwide, both present and up to 2023?
  
  
• Where will the main opportunities lie from now onwards?
  
  
• Will the US continue to dominate the blood diseases treatments market? Where do the other leading pharmaceutical nations stand?
  
  
• In which stages of development are relevant pipeline products and what are their prospects?

Other benefits to you when you order this report:

• Full searchable report when you buy the company or corporate editions
  
  
• Copies can be easily printed for offline reading

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. 
 

Chapter 1: Executive Summary

Chapter 2: Blood Diseases and their Treatments

2.1 Functions of Blood

2.1.1 Haemopoiesis

2.1.2 Haemostasis

2.2 Anaemia

2.2.1 Iron Deficiency

2.2.2 Anaemia of Chronic Disease

2.2.3 Megaloblastic Anaemia

2.2.4 Pernicious Anaemia

2.2.5 Aplastic Anaemia

2.2.6 Haemolytic Anaemia

2.2.6.1 Inherited Haemolytic Anaemia: Hereditary Spherocytosis, Hereditary Elliptocytosis, Thalassaemia, Sickle Cell Disease and Glucose-6-phosphate Deficiency

2.2.6.2 Acquired Haemolytic Anaemia: Autoimmune Haemolytic Anaemia and Non-immune Haemolytic Anaemia

2.2.7 Anaemia and Aging

2.3 Myeloproliferative and Myelodysplastic Disorders

2.3.1 Polycythaemia: Polycythaemia Vera and Secondary Polycythaemia

2.3.2 Primary Thrombocythaemia

2.3.3 Primary Myelofibrosis (Myelosclerosis)

2.4 Bleeding Disorders

2.4.1 Autoimmune Thrombocytopenic Purpura

2.4.2 Inherited Coagulation Disorders

2.4.2.1 Haemophilia A

2.4.2.2 Haemophilia B

2.4.2.3 Von Willebrand's Disease

2.4.3 Acquired Coagulation Disorders

2.4.3.1 Disseminated Intravascular Coagulation

2.5 White Blood Cell Disorders

2.5.1 Neutropenia

2.6 Thrombosis

2.6.1 Arterial Thrombosis

2.6.2 Venous Thrombosis

Chapter 3: Blood Diseases Treatments

3.1 Antithrombotic Treatments

3.1.1 Platelet Aggregation Inhibitors

3.1.2 Anticoagulants Injectable

3.1.3 Anticoagulants Non-injectable

3.1.4 Fibrinolytics

3.1.5 Direct Thrombin Inhibitors

3.1.6 Antithrombin III and Other Protease Inhibitors

3.1.7 Other Antithrombotic Treatments

3.2 Anti-anaemic Treatments

3.2.1 Erythropoietin Products

3.2.2 Iron Replacement Therapy

3.2.3 Other Anti-anaemic Treatments

3.3 Clotting Factors

3.4 Other Treatments

Chapter 4: Blood Diseases Treatments World Market

4.1 Market Analysis

4.2 Market Shares

4.3 Top Ten Drugs

4.4 Percentage Change 2006-2013

Chapter 5: Antithrombotics Market

5.1 Market Analysis

5.2 The Platelet Aggregation Inhibitors Dominate the Antithrombotics Market

5.3 Drugs Generating below $300m dominate the Antithrombotics Market

5.4 Platelet Aggregation Inhibitors Market

5.5 Plavix Dominates the Platelet Aggregation Inhibitors Market

5.6 Plavix

5.6.1 Threat to Plavix’s Sales in 2006

5.6.2 Plavix’s Competitors

5.6.3 Plavix's Loss of Patent Protection

5.7 Clopidogrel Aptx's Withdrawal

5.8 Pletaal

5.8.1 Pletaal's Indications

5.8.2 Potential Market Expansion for Pletaal

5.9 Integrilin

5.9.1 The Leading Glycoprotein IIb/IIIa Receptor Inhibitor

5.9.2 Integrilin's Competitors

5.9.3 Potential Market Expansion for Integrilin

5.10 Injectable Anticoagulants Market

5.11 Lovenox Dominates the Injectable Anticoagulants Market

5.12 Lovenox

5.12.1 A Leading Low Molecular Weight Heparin

5.12.2 Lovenox's Loss of Patent Protection in 2012

5.12.3 Potential Market Expansion for Lovenox

5.12.4 Lovenox's Competitors

5.13 Fraxiparine

5.14 Fragmin

5.15 Other Anti-thrombotics

Chapter 6: Anti-anaemics World Market

6.1 Market Analysis

6.2 Erythropoietin Products Dominate the Anti-anaemics Market

6.3 Aranesp Dominates the Anti-anaemics Market

6.4 Erythropoietin Products

6.5 Aranesp Dominates the Erythropoietin Products Market

6.6 Aranesp

6.6.1 Fears over Erythropoietin Products Overuse

6.6.2 Scope for Expansion of Aranesp’s Indications

6.6.3 Aranesp’s Edge over Competitors

6.6.4 Other Competitiors of Aranesp

6.6.5 Entry of Erythropoietin Biosimilars in Europe

6.7 Erypo

6.7.1 Generic versions of Erypo

6.8 Epogen

6.9 NeoRecormon

6.10 Espo

6.11 Iron Replacement Therapy

6.12 Drugs with Revenues less than $300m Dominate the Iron Replacement Therapy Market

6.13 Venofer

6.14 Other Anti-Anaemics

Chapter 7: Clotting Factors Market

7.1 Market Analysis

7.2 Novoseven's Change in Market Share

7.3 NovoSeven

Chapter 8: Forces Affecting the Blood Diseases Treatments Market

8.1 SWOT Analysis of the Blood Diseases Treatments Market

8.2 Market Drivers

8.3 Market Restraints

8.4 Plavix and Parallel Trade

8.5 Strong developmental Pipeline for Drugs on Parr with Lovenox

8.6 Ongoing Fears Over the use of Erythropoietin Products in Cancer Patients

8.7 FDA Approves New Haemophilia Treatment

Chapter 9: Geographical Breakdown of the Blood Diseases Treatments Market

9.1 The US Holds over 50% Market Share of the Blood Diseases Treatments Market

9.2 Increasing Market Share of Developing Countries at the Cost of Developed Countries

Chapter 10: Pipeline Products

10.1 Anti-thrombotics in the Pipeline

10.2 Anti-Anaemics in the Pipeline

10.3 Clotting Factors in the Pipeline

10.4 Other Blood Diseases Treatments in the Pipeline

Chapter 11: Conclusion

11.1 Blood Diseases and Treatments

11.2 Blood Diseases Treatments World Market

11.3 Blood Diseases Treatments Market Segments

11.4 Issues and Opportunities

11.5 Products in Development

11.6 Geographical Breakdown of the Market

11.7 Afterword

List of Tables

Table 4.1: Forecasts for Blood Diseases Treatments, 2006-2013

Table 4.2: Forecasts for Blood Diseases Treatments 2018 and 2023

Table 4.3: Top Ten Products in the Blood Diseases Treatment World Market 2006

Table 5.1: Antithrombotics Market Forecast, 2006-2013

Table 5.2: Forecasts for Platelet Aggregation Inhibitors, 2006-2013

Table 5.3: Forecasts for Platelet Aggregation Inhibitors, 2018 and 2023

Table 5.4: Injectable Anticoagulants Market Forecast, 2006-2013

Table 5.5: Injectable Anticoagulants Market Forecast, 2018 and 2023

Table 6.1: Anti-anaemics Market Forecast, 2006-2013

Table 6.2: Anti-anaemics Market Forecast, 2018 and 2023

Table 6.3: Forecasts for Erythropoietin Products, 2006-2013

Table 6.4: Forecasts for Erythropoietin Products, 2018 and 2023

Table 6.5: Forecasts for Iron Replacement Therapy, 2006-2013

Table 6.6: Forecasts for Iron Replacement Therapy, 2018 and 2023

Table 7.1: Forecasts for Clotting Factors, 2006-2013

Table 7.2: Forecasts for Clotting Factors, 2018 and 2023

Table 8.1: A SWOT Chart for the Blood Diseases Treatments Market, 2006-2013

Table 9.1: Revenue and Market Share of the Leading Pharmaceutical Markets, 2006 and 2013

Table 10.1: Platelet Aggregation Inhibitors in Development, 2008

Table 10.2: Injectable Anticoagulants in Development, 2008

Table 10.3: Other Antithrombotics in Development, 2008

Table 10.4: Erythropoietin Products in Development, 2008

Table 10.5: Other Anti-anaemics in Development, 2008

Table 10.6: Clotting Factors in Development, 2008

Table 10.7: Other Blood Diseases Treatments in Development, 2008

Table 11.1: Forecasts for Blood Diseases Treatments, 2006-2013

List of Figures

Figure 4.1: Forecasts for Blood Diseases Treatments by Market Segment, 2006-2013

Figure 4.2: Blood Diseases Treatments World Market Forecast, 2006-2013

Figure 4.3: Blood Diseases Treatments Market Share, 2006

Figure 4.4: Blood Diseases Treatments Market Share, 2013

Figure 4.5: Changes in Market Share of the Market Segments

Figure 4.6: Market Share of the Main Drugs, 2006

Figure 4.7: Market Share of the Main Drugs, 2013

Figure 4.8: Changes in revenue from 2006 to 2013 by Market Segment

Figure 5.1: Antithrombotics Market Forecast, 2006-2013

Figure 5.2: Antithrombotics Market Share, 2006

Figure 5.3: Antithrombotics Market Share, 2013

Figure 5.4: Market Share of the Main Antithrombotics, 2006

Figure 5.5: Market Share of the Main Antithrombotics, 2013

Figure 5.6: Forecasts for Platelet Aggregation Inhibitors, 2006-2013

Figure 5.7: Platelet Aggregation Inhibitors Market Forecast, 2006-2013

Figure 5.8: Market Share of Platelet Aggregation Inhibitors, 2006

Figure 5.9: Market Share of Platelet Aggregation Inhibitors, 2013

Figure 5.10: Plavix Forecast, 2006-2013

Figure 5.11: Clopidogrel Aptx Forecast, 2006-2013

Figure 5.12: Pletaal Forecast, 2006-2013

Figure 5.13: Integrilin Forecast, 2006-2013

Figure 5.14: Forecasts for Injectable Anticoagulants, 2006-2013

Figure 5.15: Injectable Anticoagulants Market Forecast, 2006-2013

Figure 5.16: Injectable Anticoagulants Market Share, 2006

Figure 5.17: Injectable Anticoagulants Market Share, 2013

Figure 5.18: Lovenox Forecast, 2006-2013

Figure 5.19: Fraxiparine Forecast, 2006-2013

Figure 5.20: Fragmin Forecast, 2006-2013

Figure 6.1: Anti-anaemics Market Forecast, 2006-2013

Figure 6.2: Anti-anaemics Market Share, 2006-2013

Figure 6.3: Anti-anaemics Market Share, 2006-2013

Figure 6.4: Market Share of the Main Anti-anaemics, 2006

Figure 6.5: Market Share of the Main Anti-anaemics, 2013

Figure 6.6: Forecasts for Erythropoietin Products, 2006-2013

Figure 6.7: Erythropoietin Products Market Forecast, 2006-2013

Figure 6.8: Erythropoietin Products Market Share, 2006

Figure 6.9: Erythropoietin Products Market Share, 2013

Figure 6.10: Aranesp Forecast, 2006-2013

Figure 6.11: Erypo Forecast, 2006-2013

Figure 6.12: Epogen Forecast, 2006-2013

Figure 6.13: NeoRecormon Forecast, 2006-2013

Figure 6.14: Espo Forecast, 2006-2013

Figure 6.15: Forecasts for Iron Replacement Therapy, 2006-2013

Figure 6.16: Iron Replacement Therapy Market Forecast, 2006-2013

Figure 6.17: Iron Replacement Therapy, 2006

Figure 6.18: Iron Replacement Therapy Market Share 2013

Figure 6.19: Venofer Forecast, 2006-2013

Figure 7.1: Forecasts for Clotting Factors, 2006-2013

Figure 7.2: Clotting Factors Market Forecast, 2006-2013

Figure 7.3: Clotting Factors Market Share, 2006

Figure 7.4: Clotting Factors Market Share, 2013

Figure 7.5: NovoSeven Forecast, 2006-2013

Figure 9.1: Revenue of the Leading Pharmaceutical Markets, 2006 and 2013

Figure 9.2: Market Share of the Leading Pharmaceutical Markets, 2006 and 2013

Figure 11.1: Blood Diseases Treatments World Market Forecast, 2006-2013

Figure 11.2: Market Share of the Main Drugs, 2006

Figure 11.3: Market Share of the Main Drugs, 2013

Figure 11.4: Changes in revenue from 2006 to 2013 by Market Segment

Figure 11.5: Forecasts for Blood Diseases Treatments by Market Segment, 2006-2013

Figure 11.6: Market Share of the Leading Pharmaceutical Markets, 2006 and 2013

 
 

---

More Details

Organisations Mentioned in this Report

Advancell

Affymax

Akzo Nobel

AMAG

Amgen

Apotex

Artisan

Asahi Kasei

AstraZeneca

Barcelona University

Barr

Baxter International

Bayer

Berlex

Boehringer Ingelheim

Bristol-Myers Squibb

Cogentus

Daiichi Sankyo

Eli Lilly

Emisphere

Flamel Technologies

Fuso

GlaxoSmithKline

Green Cross Corporation

Hexal

Hospira

Human Genome Sciences

JCR Pharmaceuticals

Johnson & Johnson

Kissei

Ligand

Lundbeck

Medicines Company

MedImmune

Menarini

National Cancer Institute

National Institutes of Health

Nektar

Novartis

Novo Nordisk

Nuvelo

Ono

Ormont

Ortho-McNeil

Otsuka

Ovation Pharmaceuticals

PAION

PeriCor

Pfizer

Protherics

RHEI

Roche

sanofi-aventis

Schering-Plough

Servier

Snow Brand Milk Products

Stada

Takeda

Taro

Torii

Ube

Watson

Wyeth